NCT01922336View on ClinicalTrials.gov

Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Healthy
Interventions
BIOLOGICAL

SB2

IV infusion

BIOLOGICAL

EU Remicade

IV infusion

BIOLOGICAL

US Remicade

IV infusion

Trial Locations (1)

Unknown

Parexel International GmbH, Berlin

All Listed Sponsors
lead

Samsung Bioepis Co., Ltd.

INDUSTRY

NCT01922336 - Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects | Biotech Hunter | Biotech Hunter